Options de traitement systémique, Centre de Preuves en Dermatologie

Guidelines atopic dermatitis Updated on Jul 25

Responsibility

The information provided by this website comes from sources deemed reliable. However, the Société Française de Dermatologie recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The Société Française de Dermatologie cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

I have read and accept the general conditions of use of this website

Back to decision-making tree Print last updated on 08/02/2026

Cyclosporine

Currently the 1^st line treatment when systemic therapy is indicated, with Marketing Authorization (MA) and reimbursement in France for adults and adolescents aged 16 and over.

In adults:

Start treatment at a high dose (4 to 5 mg/kg/day in adults) to rapidly control the disease. Treatment should be continued for a limited duration.

Regarding safety, cyclosporine requires close monitoring of blood pressure and renal function.

Doses in adults:

4 to 5 mg/kg/day in 2 doses for an acute flare-up, and 2.5 to 3 mg/kg/day in 2 doses for the long term.

Concomitant use of emollients, TCS, and TCIs is possible.

The combination of cyclosporine and phototherapy is to be avoided due to the risk of skin cancer.

In adolescents over 16 years old, to rapidly control the disease and for a limited duration:

Doses in adolescents (authorized from 16 years of age):

2.5 to 5 mg/kg/day in two daily doses

➜ Dupilumab

Back to decision-making tree Print

Was this article helpful to you?
Your opinion counts!

This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.